# Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL

> **NCT03123887** · — · COMPLETED · sponsor: **Harbin Hematology and Oncology Institute** · enrollment: 632 (actual)

## Conditions studied

- B-precursor Acute Lymphoblastic Leukemia

## Interventions

- **OTHER:** salvage therapy

## Key facts

- **NCT ID:** NCT03123887
- **Lead sponsor:** Harbin Hematology and Oncology Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-10
- **Primary completion:** 2016-06-03
- **Final completion:** 2016-10-10
- **Target enrollment:** 632 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123887, "Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03123887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*